Complete remission of heavily treated ovarian clear cell carcinoma with ARID1A mutations after pembrolizumab and bevacizumab combination therapy: a case report.

Yu-Chien LinKuo-Chang WenPi-Lin SungYu-Ting ChouPhui-Ly LiewLin-Yu ChenRui-Lan HuangHung-Cheng LaiLu-Te Chang

Published in: Journal of ovarian research (2020)

The therapeutic effect of checkpoint inhibitors combined with angiogenesis inhibitors is very promising in our patient with OCCC. Further clinical trials of tumors including ARID1A mutations are warranted.

Keyphrases

combination therapy
clinical trial
dna damage
endothelial cells
cell cycle
advanced non small cell lung cancer
disease activity
vascular endothelial growth factor
randomized controlled trial
cell proliferation
metastatic colorectal cancer
open label
wound healing
epidermal growth factor receptor
phase iii